1
|
A MencinJ KluweRF SchwabeToll-like
receptors as targets in chronic liver
diseasesGut58704720200910.1136/gut.2008.15630719359436
|
2
|
S AkiraToll-like receptor signalingJ Biol
Chem2783810538108200310.1074/jbc.R30002820012893815
|
3
|
S FrantzG ErtlJ BauersachsMechanisms of
disease: Toll-like receptors in cardiovascular diseaseNat Clin
Pract Cardiovasc Med4444454200710.1038/ncpcardio093817653117
|
4
|
S AkiraS UematsuO TakeuchiPathogen
recognition and innate
immunityCell124783801200610.1016/j.cell.2006.02.01516497588
|
5
|
JY KangX NanMS JinRecognition of
lipopeptide patterns by Toll-like receptor 2-Toll-like receptor 6
heterodimerImmunity31873884200910.1016/j.immuni.2009.09.01819931471
|
6
|
AH SchoneveldI HoeferJP SluijterJD LamanDP
de KleijnG PasterkampAtherosclerotic lesion development and Toll
like receptor 2 and 4
responsivenessAtherosclerosis19795104200810.1016/j.atherosclerosis.2007.08.00417888930
|
7
|
X LiuT UkaiH YumotoToll-like receptor 2
plays a critical role in the progression of atherosclerosis that is
independent of dietary
lipidsAtherosclerosis196146154200810.1016/j.atherosclerosis.2007.03.02517466307
|
8
|
AE MullickPS TobiasLK CurtissModulation of
atherosclerosis in mice by Toll-like receptor 2J Clin
Invest11531493156200510.1172/JCI2548216211093
|
9
|
S KuwahataS FujitaK OriharaHigh expression
level of Toll-like receptor 2 on monocytes is an important risk
factor for arteriosclerotic
diseaseAtherosclerosis209248254201010.1016/j.atherosclerosis.2009.08.04619766998
|
10
|
C MonacoN TerrandoKS MidwoodToll-like
receptor signaling: common pathways that drive cardiovascular
disease and rheumatoid arthritisArthritis Care Res
(Hoboken)63500511201110.1002/acr.2038221452263
|
11
|
AE MullickK SoldauWB KiossesTA Bell IIIPS
TobiasLK CurtissIncreased endothelial expression of Toll-like
receptor 2 at sites of disturbed blood flow exacerbates early
atherogenic eventsJ Exp
Med205373383200810.1084/jem.2007109618250194
|
12
|
Y AbeA KawakamiM OsakaApolipoprotein CIII
induces monocyte chemoattractant protein-1 and interleukin 6
expression via Toll-like receptor 2 pathway in mouse
adipocytesArterioscler Thromb Vasc
Biol3022422248201010.1161/ATVBAHA.110.210427
|
13
|
F CaoA CastrilloP TontonozF ReGI
ByrneChlamydia pneumoniae-induced macrophage foam cell
formation is mediated by Toll-like receptor 2Infect
Immun75753759200710.1128/IAI.01386-06
|
14
|
A ZerneckeE ShagdarsurenC WeberChemokines
in atherosclerosis: an updateArterioscler Thromb Vasc
Biol2818971908200810.1161/ATVBAHA.107.161174
|
15
|
RR KoenenC WeberTherapeutic targeting of
chemokine interactions in atherosclerosisNat Rev Drug
Discov9141153201010.1038/nrd304820118962
|
16
|
CW NiDL WangSC LienJJ ChengYJ ChaoHJ
HsiehActivation of PKC-epsilon and ERK1/2 participates in
shear-induced endothelial MCP-1 expression that is repressed by
nitric oxideJ Cell
Physiol195428434200310.1002/jcp.1025912704652
|
17
|
PG ArndtN SuzukiNJ AvdiKC MalcolmGS
WorthenLipopolysaccharide-induced c-Jun NH2-terminal kinase
activation in human neutrophils: role of phosphatidylinositol
3-Kinase and Syk-mediated pathwaysJ Biol
Chem2791088310891200410.1074/jbc.M30990120014699155
|
18
|
DW ParkK BaekJR KimResveratrol inhibits
foam cell formation via NADPH oxidase 1-mediated reactive oxygen
species and monocyte chemotactic protein-1Exp Mol
Med41171179200910.3858/emm.2009.41.3.02019293636
|
19
|
CS TsaiFY LinYH ChenCilostazol attenuates
MCP-1 and MMP-9 expression in vivo in LPS-administrated
balloon-injured rabbit aorta and in vitro in LPS-treated monocytic
THP-1 cellsJ Cell Biochem1035466200810.1002/jcb.2138817516547
|
20
|
JG LeeSH LeeDW ParkToll-like receptor
9-stimulated monocyte chemoattractant protein-1 is mediated via
JNK-cytosolic phospholipase A2-ROS signalingCell
Signal20105111200810.1016/j.cellsig.2007.09.00317939949
|
21
|
V BraunersreutherF MachS SteffensThe
specific role of chemokines in atherosclerosisThromb
Haemost97714721200717479181
|
22
|
R AhmadS El BassamP CordeiroJ
MenezesRequirement of TLR2-mediated signaling for the induction of
IL-15 gene expression in human monocytic cells by
HSV-1Blood11223602368200810.1182/blood-2008-02-13771118583567
|
23
|
JE ParkYI KimAK YiProtein kinase D1 is
essential for MyD88-dependent TLR signaling pathwayJ
Immunol18263166327200910.4049/jimmunol.080423919414785
|
24
|
S ChenR SorrentinoK ShimadaChlamydia
pneumoniae-induced foam cell formation requires MyD88-dependent
and -independent signaling and is reciprocally modulated by liver X
receptor activationJ
Immunol18171867193200810.4049/jimmunol.181.10.7186
|
25
|
S OkugawaY OtaT KitazawaJanus kinase 2 is
involved in lipopolysaccharide-induced activation of macrophagesAm
J Physiol Cell
Physiol285C399C408200310.1152/ajpcell.00026.200312686512
|
26
|
K KamezakiK ShimodaA NumataT MatsudaK
NakayamaM HaradaThe role of Tyk2, Stat1 and Stat4 in LPS-induced
endotoxin signalsInt
Immunol1611731179200410.1093/intimm/dxh11815226272
|
27
|
S RebouissouM AmessouG CouchyFrequent
in-frame somatic deletions activate gp130 in inflammatory
hepatocellular tumoursNature457200204200910.1038/nature07475
|
28
|
R RosellJ Bertran-AlamilloMA MolinaM
TaronIL-6/gp130/STAT3 signaling axis in cancer and the presence of
in-frame gp130 somatic deletions in inflammatory hepatocellular
tumorsFuture Oncol5305308200910.2217/fon.09.319374537
|
29
|
IT LeeCW LeeWH TungCooperation of TLR2
with MyD88, PI3K, and Rac1 in lipoteichoic acid-induced
cPLA2/COX-2-dependent airway inflammatory responsesAm J
Pathol17616711684201010.2353/ajpath.2010.09071420167866
|
30
|
GT BrownTM McIntyreLipopolysaccharide
signaling without a nucleus: kinase cascades stimulate platelet
shedding of proinflammatory IL-1beta-rich microparticlesJ
Immunol18654895496201110.4049/jimmunol.100162321430222
|
31
|
N HirataY YanagawaK IwabuchiK
OnoeSelective regulation of interleukin-10 production via Janus
kinase pathway in murine conventional dendritic cellsCell
Immunol258917200910.1016/j.cellimm.2009.03.00619361784
|
32
|
M MartinK RehaniRS JopeSM
MichalekToll-like receptor-mediated cytokine production is
differentially regulated by glycogen synthase kinase 3Nat
Immunol6777784200510.1038/ni122116007092
|